News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Avicanna says 2022 was transformational despite challenging cannabis market

Avicanna Inc

Avicanna Inc CEO Aras Azadian joined Proactive's Natalie Stoberman with the company's Year in Review including milestones reached in 2022. Azadian said 2022 was challenging for both the biopharmaceutical and cannabis industries. Despite the challenges, Azadian said it was transformational year for Avicanna as it remained focused and deliver on its business plan. Avicanna's aim in 2022 was to commercialize and advance the intellectual property portfolio across its four business units: Active Pharmaceutical Ingredients, Cosmetics, Medical, and Pharmaceutical, which contributed to successful exports to 18 international markets. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

February 03, 2023 12:02 PM Eastern Standard Time

Video
Article thumbnail News Release

Applied UV (NASDAQ: AUVI) Effectively Doubles Its Size Following A Merger That Could Help Shape The Industry – A Brief Look At The Company

Applied UV, Inc.

By Ernest Dela Aglanu, Benzinga A recent merger between Applied UV Inc. (NASDAQ CM: AUVI), Puro Lighting (PURO), and LED Supply Co. (LED Supply) seems to have triggered some excitement in the ultraviolet (UV) disinfection equipment industry. For industry watchers, particularly investors, who are constantly on the hunt for viable investment opportunities, the merger could be on their radar, especially as such a deal can shape the sector’s future. Address A Growing UV Disinfection Market Applied UV believes that the PURO merger further positions it to address a growing air disinfection market trend that aligns with the White House Clean Air Initiatives implemented during the height of the COVID-19 pandemic. The initiative was designed to protect consumers and businesses against existing and future airborne pathogens allowing economies globally to remain open. In terms of the overwhelming opportunities the deal presents, Max Munn, CEO of Applied UV, explained in a press release that it heightened the significant synergies between Applied UV and PURO. The company's acquisition of PURO adds a powerful monitoring software platform that opens new opportunities to interconnect its portfolio of UV technology solutions. Puro already has a strong presence in various sectors, such as education, government, and healthcare. These sectors have some of the strongest growth opportunities in the category, and the company believes that specializations in these sectors complement the current sectors that Sterilumen serves — food Storage, food processing, cannabis and horticulture. “These mergers expand our addressable market significantly, and PURO’s strong, strategic relationship with Acuity and national distributors provides us with additional opportunities to advance our growth agenda and increase returns for our investors,” he said. Applied UV is eyeing being a leading player in an ever-growing UV disinfection equipment industry which also has players like Xylem Inc. (NYSE: XYL), Xenon Pharmaceuticals Inc. (NASDAQ: XENE), Halma Plc. (LON: HLMA) and Calgon Carbon Corp. Currently, there is an increase in the adoption of UV in medical care, fueling the growth of the global disinfection equipment market. The market is anticipated to reach $6.17 billion by 2030 and is expected to expand at a compound annual growth rate (CAGR) of 5.7% from 2022 to 2030. Grand View Research observed that increased government initiatives and rising demand for UV disinfection equipment from healthcare organizations will continue to drive the sector’s growth. The technology and work of companies like Applied UV can never be overlooked, especially in medical care. Increasingly, countless industries, such as healthcare, are realizing the benefits of protecting patients and preventing infection with UV light disinfection at health facilities. For example, UVC radiation emitted by UV germicidal lamps is known to effectively breach the cells of microorganisms, making them non-viable and unable to replicate or infect patients and medical personnel at hospitals. Applied UV prides itself as a global leader that applies the power of narrow-range ultraviolet light for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically. Two Subsidiaries And Segments The company’s major selling point could be its two wholly-owned subsidiaries — SteriLumen Inc. and Munn Works LLC. SteriLumen offers a portfolio of technologically advanced, energy-efficient air purifier and surface disinfectant systems: Airocide® by Sterilumen, Scientific Air™ by Sterilumen and Lumicide™ by Sterilumen. SteriLumen’s connected platform for Data Driven Disinfection™ applies the power of ultraviolet light to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections. Airocide®’s applications include healthcare, hospitality, grocery chains, wine-making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities and homes. Targeted for use in facilities with high customer turnover, such as hospitals, hotels, commercial facilities, and other public spaces. The Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The company’s second subsidiary, Munn Works, is a global company that manufactures the highest quality mirrors and case goods. From statement pieces that have the impact of original art to meticulous high-volume production for guest rooms or multi-family projects, the company works closely with designers to achieve the perfect balance of aesthetics and economics. The company has the following reportable segments that are driving growth: Disinfection segment: The design, manufacture, assembly and distribution of disinfecting systems for use in healthcare, hospitality, food, wine, and commercial municipal and residential markets. The disinfection segment addresses heating, ventilation, and air conditioning (HVAC) in public, government, municipal, retail spaces and buildings. Hospitality segment: The manufacture of fine mirrors and furniture specifically for the hospitality industry. Applied UV’s merger with LED Supply is key here. LED Supply is a strong player in the commercial lighting space, and the company hopes to bring expertise in design and specification for the multifamily space. It complements the hospitality category and will lead to synergistic revenue opportunities for Munn Works and LED Supply. SG&A Translating Into Cost Reductions? Apart from the broader addressable market and cross-selling opportunities, including increasing revenues, the merger could present synergies that might ultimately translate into cost reductions. A cursory look at Applied UV’s financial results for Q3 2022 showed that Selling, General, and Administrative (SG&A costs for the three months ended September 30, 2022, increased to $3.5 million compared to $2.7 million for the three months ended September 30, 2021. This increase of approximately $822,000 was driven primarily by the expansion of the disinfection segment with the acquisition of KES and SciAir; the expansion of the hospitality segment with the addition of the VisionMark acquisition; and corporate segment expenses due to increased consulting, legal, accounting and infrastructure costs related to the initial integration of the operations of the company’s strategic acquisitions. SG&A costs decreased by $526,000 from last quarter, and the company anticipates efficiency gains this year as it fully integrates its acquisitions and leverages synergies where practical. With a larger team that will collaborate on sales and marketing strategies, new product development, and engineering now at its disposal, Applied UV could eye new acquisitions that could lead to revenue growth for investors and value for customers. For investors looking to invest in medical technology companies or stocks, Applied UV’s growth potential could be very attractive. This article was originally published on Benzinga here. Applied UV is focused on the development and acquisition of technology that addresses infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s Airocide® air purification devices are research-backed, clinically proven, and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photo-catalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors, and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine-making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities, and homes. SteriLumen’s connected platform for Data-Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company’s Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The Company’s patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen-intensive location. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Brett Maas- Hayden IR brett@haydenir.com Company Website https://www.applieduvinc.com/

February 03, 2023 09:25 AM Eastern Standard Time

Article thumbnail News Release

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results

BioRestorative Therapies, Inc.

By Julian Richard, Benzinga Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony discs in the lower back. While its exact cause is unknown, factors such as age, obesity, poor posture, and overuse of the lumbar spine are believed to be contributing factors. The burden of chronic lumbar disc disease is significant, with the World Health Organization estimating that up to 75% of adults will experience some form of chronic back pain throughout their lifetime. It is also estimated that 10-15% of those affected will have a long-term disability due to their condition. To address the unmet need for an effective and safe way of treating this burdensome condition, BioRestorative Therapies (NASDAQ: BRTX) launched a Phase 2 double-blind, controlled, randomized study of BRTX-100 in 99 American patients. BRTX-100 is an innovative technology that uses the patient’s cells to repair damage to discs in the back. Phasing Into Bigger Future Production? The phase 2 study is evaluating the initial efficacy and safety of a single dose of BRTX-100 compared to saline injected into the affected disk in the spine. Although the primary endpoints will be unblinded after all 99 patients have been treated, a critical milestone for BRTX is scheduled in March or April 2023 related to the safety profile of the product. An independent group of experts will assess the safety data of the first four patients treated in the study. This board of experts decides if a study can continue, if there needs to be changes in the way the study is conducted or if the study should be stopped entirely. BRTX is confident that the data from the study will show that BRTX-100 is safe in treating cLLD. The outcome of the board examination will have a critical impact on its next moves — “Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.” In anticipation of positive findings from this study, BRTX is increasing its manufacturing and quality control capacity and hiring new scientists to meet the demands for the BRTX-100 Phase 2 enrollment. The additional demand is expected not only for the phase 2 study in cLLD but for studies in other conditions affecting the neck, knee and hip. Clearing the safety hurdle of the trial enables the Company to expand its BRTX-100 platform into other indications more easily and at a greater pace. Other companies in the stem cell therapy sector of the biotech industry include Sanofi (NASDAQ: SNY), Vertex Pharmaceuticals (NASDAQ: VRTX) and BioMarin Pharmaceutical (NASDAQ: BMRN). Visit biorestorative.com for more information on the company and its product candidates. This article was originally published on Benzinga. BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations ir@biorestorative.com Company Website https://www.biorestorative.com/

February 03, 2023 09:25 AM Eastern Standard Time

Article thumbnail News Release

Avricore Health looks to continue positive growth in 2023 after success in 2022

Avricore Health

Avricore Health CEO Hector Bremner joined Proactive's Steve Darling with an update on the company's 2022 performance and the goals it has set for 2023. Bremner told Proactive more about Avricore's key HealthTab offering and the scaling it saw in 2022. He also shared his vision for 2023, which includes further expansion of HealthTab with current partners, international expansion, and revenue growth and profitability. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

February 02, 2023 01:05 PM Eastern Standard Time

Video
Article thumbnail News Release

Tonix Pharmaceuticals discusses exclusive license of potential monoclonal antibodies

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Seth Lederman joined Proactive's Natalie Stoberman to discuss the exclusive license of potential monoclonal antibodies from Curia Global, a leading contract research, development and manufacturing organization. Lederman said Tonix has obtained an exclusive license for the development of three humanized murine monoclonal antibodies for the treatment or prophylaxis of SARS-CoV-2 infection. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

February 02, 2023 12:15 PM Eastern Standard Time

Video
Article thumbnail News Release

Delivra Health Brands says Dream Water to be sold across Hilton Hotels

Delivra Health Brands Inc.

Delivra Health Brands CEO Gord Davey joined Proactive's Natalie Stoberman to announce the company's Dream Water products are being distributed across 450 Hilton Hotels in the US. Davey told Proactive that Delivra's Dream Water brand offers sleep aids in a variety of formats and formulations. Dream Water currently produces convenient, travel-friendly, single-serving 2.5oz liquid sleep shots, sleep powder packets that consumers can take with or without water, and gummies. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

February 02, 2023 11:39 AM Eastern Standard Time

Video
Article thumbnail News Release

Roberts & Ryan welcomes our latest new hires to our growing Equity Trading Team

Roberts & Ryan Investments, Inc.

Roberts & Ryan welcomes our latest new hires to our growing Equity Trading Team: Brian Scala, Mario Lagana and Andrew Darcy. BRIAN SCALA Mr. Brian Scala brings more than 25 years of experience to Roberts & Ryan, focusing primarily on Equity and Options trading and compliance. Prior to joining Roberts & Ryan, Mr. Scala was a Senior Vice President & Head of Equity Trading at Drexel Hamilton, LLC, a Veteran-owned investment bank. Prior to that, Mr. Scala was Executive Director of Institutional Sales Trading at O’Neil Securities, Inc., where he was an Equity trader for institutional clients, Chief Options Compliance Officer and Head of the Equity Technology Department. Mr. Scala was also the CEO and Chief Equity and Options Compliance Officer for the Equity Trading Division of Clancy Financial Services. Prior to Clancy Financial Services, Mr. Scala was a NYSE Floor Broker for Troy Securities, the Head NASDAQ Sales Trader at KV Execution and a NYSE Floor Clerk for PSK Securities. Mr. Scala holds SIE and FINRA Series 4, 7, 24, 25, 55 & 63 licenses. MARIO LAGANA Mr. Mario Lagana brings over 30 years of Wall Street and management experience to Roberts & Ryan. He has traded all forms of Equities, trading investments and risk management. Mr. Lagana will oversee new business development and day to day operations. "As Senior Director at Roberts & Ryan, my ultimate goal is to offer Roberts & Ryan’s clients the best service available on Wall Street,” says Mr. Lagana. Having built trading desks at firms such as Drexel Hamilton, William O’ Neil and Robbins & Henderson, Mr. Lagana understands the commitment it takes to deliver added value. Modeled as an extension of a buy-side desk, Roberts & Ryan presents a trading desk dedicated to best execution. At the inception of his career at William O’Neil, Mr. Lagana gained technical expertise working with some of the best trading technicians in the industry. Closely mentored by William O’ Neil himself, Mr. Lagana learned fundamental and technical analysis by continuously reviewing markets, industry groups and stocks. His critical insights specialize in market direction and stock trends. Mr. Lagana holds SIE and FINRA Series 7, 55, 57, & 63 licenses. ANDREW DARCY Mr. Andrew Darcy joins Roberts & Ryan following over 25 years of Wall Street experience, focused primarily on Equity trading. Prior to joining Roberts & Ryan, Mr. Darcy was Managing Director & Head of Equity Trading at Drexel Hamilton, LLC, a Veteran-owned investment bank, where he led the secondary Equity trading department in all facets of the business, including trading, corporate buybacks, TCA, client relationships, technology, operations, compliance and business development. Prior to that, Mr. Darcy served as a Managing Director of Equity Sales Trading at BTIG and Executive Director at Morgan Stanley & Co. LLC. Prior to Morgan Stanley, Mr. Darcy was Director of Institutional Equity Sales Trading at Citigroup Global Markets, Credit Suisse AG, and Merril Lynch & Co. Mr. Darcy was a Commissioned Officer in the United States Navy, serving as a member of SEAL Team Eight and SEAL Team Four. He participated in Operation Desert Storm in the Red Sea and Operation Provide Comfort in Northern Iraq. Mr. Darcy holds FINRA Series 7, 24, 55 & 63 licenses. Mr. Scala, Mr. Lagana and Mr. Darcy are all committed to our nation’s military and, in particular, Roberts & Ryan’s service to numerous world-class Veteran causes. Roberts & Ryan’s Head of Equities, James McDevitt comments, “I’m very excited to be adding this team of equity professionals. The combined teams represent Roberts & Ryan’s commitment to equity trading and providing best in class service and execution.” About Roberts and Ryan Investments, Inc. Roberts & Ryan Investments, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over one and a half million dollars in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, primarily focusing on general wellness, mental health and career transition. Contact Details Joe Pecoraro +1 917-658-8945 jpecoraro@roberts-ryan.com Company Website https://www.roberts-ryan.com

February 02, 2023 09:00 AM Eastern Standard Time

Article thumbnail News Release

Elsevier Launches Reproductive Health Hub in the US to Support Healthcare Professionals with Free, Evidence-Based Medical Content

Elsevier

Elsevier, a global leader in evidence-based clinical practice content, research publishing and information analytics, today announced the launch of the Reproductive Health Hub to support healthcare professionals with trusted information about reproductive health topics including fertility, pregnancy, contraception, and menopause. The hub includes an extensive set of clinical guidelines on various areas of reproductive health and health issues related to pregnancy. There are resources on relevant nursing skills, such as undertaking ultrasounds, providing bereavement support and the identification and treatment of possible side effects of pregnancy. The hub will also feature educational resources for healthcare professionals to share with patients, providing valuable information on issues relating to fertility, pregnancy and menopause, as well as education on the many medications that can be used in reproductive healthcare. The evidence-based content included in the hub will be regularly reviewed to ensure it remains a reliable and current resource for all healthcare professionals working in reproductive health. Mie-Yun Lee, Head of Inclusion and Diversity at Elsevier said: “Elsevier is committed to ensuring healthcare professionals have access to reliable, evidence-based content so they can deliver the best possible outcomes for all patients. There are many pressures on today’s healthcare professionals, including increasing workloads and ongoing changes to patient care. Having all these trusted reproductive health resources in one central location will support busy clinicians and help them to provide the best possible care to their patients.” Elsevier has a suite of tools and resources designed to support healthcare professionals at every stage of their entire career, from their first day at medical school to their last day as a clinician. With huge quantities of new clinical information and best practice being generated every year, Elsevier is committed to helping clinicians stay on top of evolving medical guidance by providing continuous learning and clinical decision solutions throughout their career. The Reproductive Health Hub is the latest in a series of content centers - Elsevier ’s Healthcare Hub includes resources on diseases such as diabetes, asthma and mental health, and has also been utilized to make crucial information on health crises like Covid-19 and Mpox virus immediately available to medical professionals. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support and health education. Researchers and healthcare professionals rely on our 2,700 digitized journals, including “ The Lancet ” and “ Cell ”; our 43,000 e-Book titles; and our iconic reference works, such as “Gray’s Anatomy.” With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com. Contact Details Dan DiPietro-James Dan.james@elseiver.com Company Website https://www.elsevier.com/

February 02, 2023 09:00 AM Eastern Standard Time

Article thumbnail News Release

Tissue Regenix Group "has the opportunity to become a global commercial organisation"

Tissue Regenix Group PLC

Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF) chief executive Danny Lee and chief financial officer David Cocke speak to Proactive's Thomas Warner after releasing a trading update for 2022. They reveal their highlights from the year before looking ahead to what investors can expect from the business during 2023. Lee says that Tissue Regenix "has the opportunity to become a global commercial organisation." Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 02, 2023 05:55 AM Eastern Standard Time

Video
1 ... 167168169170171 ... 310